INT98203

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 2.38
Pain Relevance 0.34

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (KRAS) mitochondrion (KRAS) plasma membrane (KRAS)
GTPase activity (KRAS)
KRAS (Homo sapiens)
Pain Link Frequency Relevance Heat
COX-2 inhibitor 1 100.00 Very High Very High Very High
cINOD 6 92.88 High High
antagonist 2 59.36 Quite High
COX2 1 25.00 Low Low
cOX1 1 25.00 Low Low
fibrosis 8 5.00 Very Low Very Low Very Low
Inflammation 4 5.00 Very Low Very Low Very Low
agonist 4 5.00 Very Low Very Low Very Low
depression 2 5.00 Very Low Very Low Very Low
alcohol 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hepatitis C Virus Infection 292 99.98 Very High Very High Very High
Microsatellite Instability 7 99.40 Very High Very High Very High
Infection 34 98.80 Very High Very High Very High
Hepatitis 14 98.68 Very High Very High Very High
Colon Cancer 62 96.36 Very High Very High Very High
Cancer 57 94.24 High High
INFLAMMATION 7 92.32 High High
Disease 23 60.88 Quite High
Chronic Hepatitis 8 49.68 Quite Low
Exanthema 3 15.28 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Recent development of direct-acting antiviral agents, also named “specifically targeted antiviral therapy for hepatitis C” (STAT-C) compounds, to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3/4A protease and the RNA-dependent RNA polymerase NS5B [129, 130].
Negative_regulation (inhibitors) of NS3 associated with hepatitis c virus infection and hepatitis
1) Confidence 0.42 Published 2010 Journal Hepatitis Research and Treatment Section Body Doc Link PMC2990099 Disease Relevance 0.73 Pain Relevance 0
The administration of HCV NS3/4A protease inhibitors to patients with chronic HCV infections has demonstrated that they have dramatic antiviral effects and that compounds acting via this mechanism are likely to form a key component of future anti-HCV therapy [131].
Negative_regulation (inhibitors) of NS3 associated with hepatitis c virus infection and infection
2) Confidence 0.42 Published 2010 Journal Hepatitis Research and Treatment Section Body Doc Link PMC2990099 Disease Relevance 0.83 Pain Relevance 0
Loss of heterozygosity, BRAF and KRAS mutations and microsatellite instability analysis
Negative_regulation (Loss) of KRAS associated with microsatellite instability
3) Confidence 0.32 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 0.34 Pain Relevance 0.03
Mutational status of KRAS and EGFR, and EGFR copy number are potential determinants of cetuximab activity.


Negative_regulation (number) of KRAS
4) Confidence 0.19 Published 2008 Journal BMC Cancer Section Abstract Doc Link PMC2432064 Disease Relevance 0.38 Pain Relevance 0
The models are obtained for complexes of NS398 (NS), a selective COX-2 inhibitor; indoprofen (Ind), a non-selective inhibitor; di-tert-butylbenzofurans (DHDMBFs) with substituents at the 5th position: CONH(CH2)2OMe (BF1), CONH-c-Pr (BF2), 3-methylene-gamma-butyrolactonyl (BF3) and oxicams namely, meloxicam (Mel), piroxicam (Pir) and tenoxicam (Ten).
Negative_regulation (inhibitor) of NS398 associated with cox-2 inhibitor
5) Confidence 0.00 Published 2001 Journal Indian J. Biochem. Biophys. Section Abstract Doc Link 11563332 Disease Relevance 0.09 Pain Relevance 0.31

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox